Purchase this article with an account.
Y. Niwa, O. Sawada, M. Kakinoki, T. Sawada, H. Kawamura, M. Ohji; Comparison Between One Injection and Three Monthly Injections of Intervitreal Bevacizumab for Myopic Choroidal Revascularization. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2278.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization (mCNV).
Nineteen eyes of 19 patients with mCNV were treated with intravitreal bevacizumab injections. Group A included 10 patients treated with three monthly intravitreal bevacizumab (1.25 mg) injections. Group B included nine patients treated with one intravitreal bevacizumab injection. All patients were followed for 6 months from the last injection. The best-corrected visual acuity (BCVA) and the central foveal thickness (CFT) on optical coherence tomography were evaluated.
The mean logMAR BCVA at baseline was 0.66 in group A and 0.64 in group B. The mean BCVA improved to 0.34 at 6 months in group A (p=0.016) and to 0.44 in group B. There was no significant difference between the two groups (p=0.053). The mean CFT decreased from 328 µm at baseline to 173 µm in group A (p=0.004) and from 301 µm to 195 µm group B (p=0.027). The changes in BCVA and in CFT did not different between the groups. Additional injections for 6 months after the last injection were required in one of 10 eyes in group A and four of nine eyes in group B.
Intravitreal bevacizumab injections improved the BCVA and CFT. Treatment starting with three monthly injections of bevacizumab may require fewer retreatments compared with an initial single injection of bevacizumab.
This PDF is available to Subscribers Only